{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:01:49Z","timestamp":1793138509075,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study aimed to define thresholds of clinically significant change in 17\u2010item Hamilton Depression Rating Scale (HDRS\u201017) scores using the Clinical Global Impression\u2010Improvement (CGI\u2010I) Scale as a gold standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a secondary analysis of individual patient data from the Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study, an 8\u2010week, single\u2010arm clinical trial of citalopram or escitalopram treatment of adults with major depression. We used equipercentile linking to identify levels of absolute and percent change in HDRS\u201017 scores that equated with scores on the CGI\u2010I at 4 and 8\u2009weeks. Additional analyses equated changes in the HDRS\u20107 and Bech\u20106 scale scores with CGI\u2010I scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A CGI\u2010I score of 2 (much improved) corresponded to an absolute decrease (improvement) in HDRS\u201017 total score of 11 points and a percent decrease of 50\u201357%, from baseline values. Similar results were observed for percent change in HDRS\u20107 and Bech\u20106 scores. Larger absolute (but not percent) decreases in HDRS\u201017 scores equated with CGI\u2010I scores of 2 in persons with higher baseline depression severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our results support the consensus definition of response based on HDRS\u201017 scores (\n                      <jats:styled-content>&gt;<\/jats:styled-content>\n                      50% decrease from baseline). A similar definition of response may apply to the HDRS\u20107 and Bech\u20106. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hup.2526","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T21:33:29Z","timestamp":1458596009000},"page":"185-192","source":"Crossref","is-referenced-by-count":91,"title":["Validation of the 17\u2010item\n                    <scp>Hamilton Depression Rating Scale<\/scp>\n                    definition of response for adults with major depressive disorder using equipercentile linking to\n                    <scp>Clinical Global Impression<\/scp>\n                    scale ratings: analysis of\n                    <scp>Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study<\/scp>\n                    (PGRN\u2010AMPS) data"],"prefix":"10.1002","volume":"31","author":[{"given":"William V.","family":"Bobo","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychology Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela C.","family":"Angler\u00f3","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology Mayo Clinic  Rochester MN USA"},{"name":"School of Medicine University of Puerto Rico  San Juan Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Hall\u2010Flavin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weinshilboum","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Biernacka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology Mayo Clinic  Rochester MN USA"},{"name":"Department of Health Sciences Research Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.12.2163"},{"key":"e_1_2_8_3_1","first-page":"1","article-title":"Rating scales for affective disorders: their validity and consistency","volume":"295","author":"Bech P","year":"1981","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.31887\/DCNS.2006.8.2\/pbech","article-title":"Rating scales in depression: limitations and pitfalls","volume":"8","author":"Bech P","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"issue":"7","key":"e_1_2_8_5_1","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-387-5_2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(99)00037-0"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31814f30b1"},{"key":"e_1_2_8_9_1","unstructured":"GuyW.ECDEU Assessment Manual for Psychopharmacology \u2010 revised (DHEW Publ. No. ADM 76\u2010338). Rockville MD U.S. Department of Health Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration NIMH Psychopharmacology Research Branch Division of Extramural Research Programs 1976."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.3\/shkennedy"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0317-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.07.011"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.4.366"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.008"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301147"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.12.001"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2004.00440.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.010"},{"issue":"4","key":"e_1_2_8_20_1","first-page":"235","article-title":"Assessing full remission","volume":"27","author":"McIntyre R","year":"2002","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000099"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301131"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000244554.91259.27"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341757"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03035120"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2526","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T23:01:24Z","timestamp":1696374084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/hup.2526"],"URL":"https:\/\/doi.org\/10.1002\/hup.2526","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]}}}